5Kirpensteijn J,Teske E,Kik M. Lobaplatinas an adjuvant chemotherapy to surgery in canine appendicular osteosarcoma:a phase II evaluation[J].Anticancer Research,2002,(05):2765-2770.
4Chua DT,Sham JS,Wei W I,et al.The predictive value of the 1997 American joint committee on cancer stage ciassification in determining failure patterns in nasopharyngeal carcinoma.Cancer,2001,92(12):2845.
5Langendk JA,Leemans ChR,Buter J,et al.The additional va1ue of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma:ameta-analysis of the published literatttre.Clin Onco1,2004,22(22):4604.
6Ma BB,Chan AT.Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma.Cancer,2005,103 (1):22.
7V. Heinemann,H. J. Stemmler,A. Wohlrab,D. Bosse,C. Losem,S. Kahlert,G. Rauthe. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer[J] 2006,Cancer Chemotherapy and Pharmacology(5):640～646
6Monneret C. Platinum anticancer drugs. From serendipity to rational design. Ann Pharm Fr, 2011, 69(6) : 286-295.
7Wu Q, Qin SK, Teng FM, et al. Lobaplatin arrests cell cycle progres- sion in human hepatocellular carcinoma cells. J Hematol Oncol, 2010, 3: 43.
8McKeage MJ. Lobaplatin : a new antitumour platinum drug. Expert Opin Investig Drugs, 2001, 10(1) : 119-128.
9Welink J, Boven E, Vermorken JB, et al. Pharmacokinetics and pharmacodynamics of lobaplatin ( D-19466 ) in patients with advanced solid tumors, including patients with impaired renal of liv- er function. Clin Cance: Res, 1999, 5 (9) : 2349-2358.
10Al-Sarraf M, LeBlanc M,Giri PG, et al.Chemoradiotherapy versusradiotherapy in patients with advanced nasopharyngeal cancer: phaseHI randomized Intergroup study 0099. J Clin Oncol, 1998, 16: 1310-1317.
